why choose us

Clinical Trials Search

Showing 8,800 of 132,366 result(s)
Effect of Short-chain Fatty Acids on Aerobic Endurance

Status: Completed

Condition: Aerobic Endurance

Interventions: High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically add

Date: 2023-08-21

Sleep and Circadian Rhythm Biomarkers of Postoperative Delirium

Status: Completed

Condition: Delirium, Postoperative

Interventions:

Date: 2023-08-21

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Status: Completed

Condition: Colo-rectal Cancer

Interventions: Given IM

Date: 2023-08-21

CTSN Embolic Protection Trial

Status: Completed

Condition: Delirium

Interventions: The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to captu

Date: 2023-08-21

Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

Status: Completed

Condition: Migraine

Interventions: Two 4mg pills

Date: 2023-08-21

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Status: NOT_YET_RECRUITING

Condition: Cystic Fibrosis Lung

Interventions: RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer.
Each dose of RSP-1502 contains the active com

Date: 2023-08-21

A Stepped Care Approach to Treating Dental Fear

Status: Completed

Condition: Dental Fear

Interventions: Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.

Date: 2023-08-21

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

Status: ACTIVE_NOT_RECRUITING

Condition: Cocaine Use Disorder

Interventions: Multiple ascending dose active

Date: 2023-08-21

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

Status: Completed

Condition: Dermal Hypersensitivity Reaction

Interventions:

Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last

Date: 2023-08-21

Aquacel Hypersensitivity Dressing in TJAs

Status: Completed

Condition: Contact Allergic Dermatitis

Interventions: Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment.
After meeting inclusion criteri

Date: 2023-08-21